GMED Share Price | Globus Medical, Inc. Stock Analysis & Recommendation

Q: How big is Globus Medical, Inc.?

Market Cap: As of Jun 18, Globus Medical, Inc. has a market capitalization of 7,870.96 million, categorizing it as a Mid Cap company.Recent Quarterly Performance: For the latest four quarters, Globus Medical, Inc. reported net sales of 2,510.81 million and a net profit of 185.56 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 4,177.33 million and total assets of 5,251.75 million.

Q: What does Globus Medical, Inc. do?

Overview: Globus Medical, Inc. is a medical device company focused on developing products for patients with musculoskeletal disorders, specifically spine disorders, and operates in the Pharmaceuticals & Biotechnology industry within the mid-cap market.Financial Snapshot: Most recent Net Sales: 598 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 75 Million (Quarterly Results - Mar 2025) Market-cap: USD 7,870.96 Million (Mid Cap)Key Metrics: P/E: 36.00 Dividend Yield: 0.00% Debt Equity: -0.11 Return on Equity: 5.54% Price to Book: 1.93Contact Details: Address: 2560 General Armistead Ave, AUDUBON PA: 19403-5214 Tel: 1 610 9301800 Website: http://www.globusmedical.com/

Q: Is Globus Medical, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Globus Medical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, with key indicators showing mixed signals. The MACD is mildly bullish on a weekly basis but bearish monthly, while the RSI is bearish weekly with no signal monthly. Moving averages are mildly bearish on a daily basis. Additionally, the Bollinger Bands and KST indicate a mildly bullish trend weekly but are mildly bearish monthly. In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -27.25% versus 14.18% for the S&P 500, and a one-year return of -14.85% compared to 17.82% for the index.

Q: Is Globus Medical, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Globus Medical, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 36, a Price to Book Value of 1.98, and an EV to EBITDA of 13.54. Comparatively, its peers such as Masimo Corp. with a P/E of 179.74 and Merit Medical Systems, Inc. with a P/E of 42.46 suggest that Globus Medical's valuation is relatively high.In terms of performance, Globus Medical has underperformed against the S&P 500, with a year-to-date return of -25.45% compared to the index's 16.30%. This trend of underperformance, alongside its elevated valuation ratios, reinforces the conclusion that the stock is overvalued in the current market environment.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

804.33 k

Shareholding (Dec 2025)

FII

20.49%

Held by 208 FIIs

DII

31.24%

Held by 63 DIIs

Promoter

0.23%

How big is Globus Medical, Inc.?

22-Jun-2025

As of Jun 18, Globus Medical, Inc. has a market capitalization of $7.87 billion, with recent net sales of $2.51 billion and a net profit of $185.56 million.

View full answer

What does Globus Medical, Inc. do?

22-Jun-2025

Globus Medical, Inc. is a mid-cap medical device company specializing in products for musculoskeletal and spine disorders, with recent net sales of $598 million and a net profit of $75 million. The company has a market cap of approximately $7.87 billion.

View full answer

Who are in the management team of Globus Medical, Inc.?

22-Jun-2025

As of March 2022, the management team of Globus Medical, Inc. includes Executive Chairman David Paul, President and CEO David Demski, and several independent directors: David Davidar, Robert Douglas, Daniel Lemaitre, Ann Rhoads, and James Tobin.

View full answer

Is Globus Medical, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Globus Medical, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 with a year-to-date return of -27.25% compared to 14.18%.

View full answer

Is Globus Medical, Inc. overvalued or undervalued?

05-Nov-2025

As of October 31, 2025, Globus Medical, Inc. is considered overvalued with a valuation grade of "attractive," reflected by a P/E ratio of 36 and a year-to-date return of -25.45%, significantly underperforming the S&P 500's 16.30%.

View full answer

Compare Globus Medical, Inc. with Similar Stocks

Merit Medical Systems, Inc.Sotera Health Co.Haemonetics Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Company has a low Debt to Equity ratio (avg) at times

Low Debt Company with Strong Long Term Fundamental Strength

The company has declared Positive results for the last 3 consecutive quarters

With ROE of 5.54%, it has a expensive valuation with a 1.98 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 12,194 Million (Small Cap)

P/E

19.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.09

Return on Equity

11.41%

Price to Book

2.77

Revenue and Profits:

Net Sales:

826 Million

(Quarterly Results - Dec 2025)

Net Profit:

141 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-0.03%

6 Months

48.27%

1 Year

20.72%

2 Years

66.85%

3 Years

64.29%

4 Years

27.73%

5 Years

38.55%

Globus Medical, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

29.27%

EBIT Growth (5y)

27.88%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.11

Sales to Capital Employed (avg)

0.51

Tax Ratio

20.34%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

12.35%

ROE (avg)

7.98%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.94

EV to EBIT

22.31

EV to EBITDA

12.76

EV to Capital Employed

1.99

EV to Sales

3.08

PEG Ratio

0.09

Dividend Yield

ROCE (Latest)

8.90%

ROE (Latest)

10.19%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 125 Schemes (48.01%)

Foreign Institutions

Held by 208 Foreign Institutions (20.49%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 7.46% vs 3.18% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 18.15% vs -41.32% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "826.40",
          "val2": "769.00",
          "chgp": "7.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "251.30",
          "val2": "205.80",
          "chgp": "22.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.90",
          "val2": "2.70",
          "chgp": "-466.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "140.60",
          "val2": "119.00",
          "chgp": "18.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "219.80%",
          "val2": "175.10%",
          "chgp": "4.47%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 16.65% vs 60.62% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 422.23% vs -16.19% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,938.90",
          "val2": "2,519.40",
          "chgp": "16.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "818.20",
          "val2": "486.30",
          "chgp": "68.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "4.20",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-58.50",
          "val2": "-66.30",
          "chgp": "11.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "537.90",
          "val2": "103.00",
          "chgp": "422.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "184.00%",
          "val2": "92.20%",
          "chgp": "9.18%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

826.40

769.00

7.46%

Operating Profit (PBDIT) excl Other Income

251.30

205.80

22.11%

Interest

0.00

Exceptional Items

-9.90

2.70

-466.67%

Consolidate Net Profit

140.60

119.00

18.15%

Operating Profit Margin (Excl OI)

219.80%

175.10%

4.47%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 7.46% vs 3.18% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 18.15% vs -41.32% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

2,938.90

2,519.40

16.65%

Operating Profit (PBDIT) excl Other Income

818.20

486.30

68.25%

Interest

0.00

4.20

-100.00%

Exceptional Items

-58.50

-66.30

11.76%

Consolidate Net Profit

537.90

103.00

422.23%

Operating Profit Margin (Excl OI)

184.00%

92.20%

9.18%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 16.65% vs 60.62% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 422.23% vs -16.19% in Dec 2024

All Annual Results

Company CV

About Globus Medical, Inc.

Globus Medical, Inc.

Pharmaceuticals & Biotechnology

Globus Medical, Inc. is a medical device company. The Company is focused on developing products for patients with musculoskeletal disorders. It is focused on products to treat patients with spine disorders. The Company's products fall under categories, which include Innovative Fusion and Disruptive Technologies. The Innovative Fusion category products include fusion products to treat spinal disorders for the entire spine, and they can be used in various surgical approaches. The Disruptive Technologies category represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders. QUARTEX is its Occipito-Cervico-Thoracic (OCT) stabilization system. QUARTEX features a threading locking cap to enable low-torque. The Company's portfolio of approved and pipeline Disruptive Technology products includes products that allow for minimally invasive surgical (MIS) techniques.

Company Coordinates

Company Details

2560 General Armistead Ave , AUDUBON PA : 19403-5214

Tel: 1 610 9301800

http://www.globusmedical.com/

Registrar Details